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Abstract 
Triple-negative breast cancer (TNBC) cells lack the expression of ER, PR and HER2. Thus, TNBC patients 
cannot benefit from hormone receptor-targeted therapy as non-TNBC patients, but can only receive 
chemotherapy as the systemic treatment and have a worse overall outcome. More effective therapeutic 
targets and combination therapy strategies are urgently needed to improve the treatment effectiveness.  
Methods: We analyzed the expression levels of EZH2 and TET1 in TCGA and our own breast cancer 
patient cohort, and tested their correlation with patient survival. We used TNBC and non-TNBC cell 
lines and mouse xenograft tumor model to unveil novel EZH2 targets and investigated the effect of EZH2 
inhibition or TET1 overexpression in cell proliferation and viability of TNBC cells.  
Results: In TNBC cells, EZH2 decreases TET1 expression by H3K27me3 epigenetic regulation and 
subsequently suppresses anti-tumor p53 signaling pathway. Patients with high EZH2 and low TET1 
presented the poorest survival outcome. Experimentally, targeting EZH2 in TNBC cells with specific 
inhibitor GSK343 or shRNA genetic approach could induce cell cycle arrest and senescence by elevating 
TET1 expression and p53 pathway activation. Using mouse xenograft model, we have tested a novel 
therapy strategy to combine GSK343 and chemotherapy drug Adriamycin and could show drastic and 
robust inhibition of TNBC tumor growth by synergistic induction of senescence and apoptosis.  
Conclusions: We postulate that the well-controlled dynamic pathway EZH2-H3K27me3-TET1 is a 
novel epigenetic co-regulator module and provide evidence regarding how to exploit it as a novel 
therapeutic target via its pivotal role in senescence and apoptosis control. Of clinical and therapeutic 
significance, the present study opens a new avenue for TNBC treatment by targeting the 
EZH2-H3K27me3-TET1 pathway that can modulate the epigenetic landscape. 
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Introduction 
Triple-negative breast cancer (TNBC) cells lack 
expression of the estrogen receptor, progesterone 
receptor, and human epidermal growth factor 
receptor 2 (HER2) [1, 2]. Compared with non-TNBC 
patients who may benefit from chemotherapy, 
endocrine therapy and the anti-HER2 antibody 
Trastuzumab, TNBC patients only qualify for 
chemotherapy as a systemic option and have an 
inferior overall outcome [3]. Most TNBC patients 
succumb to their disease due to drug resistance and 
relapse after intensive chemotherapy, underscoring 
the urgent medical need for more effective, 
molecularly informed treatments, most likely as 
combination therapies together with chemo-drugs. 
Given the triple-lack of classic breast cancer targets, 
we hypothesized enhanced expression of repressive 
epigenetic regulators might alternatively serve as 
actionable oncogenic principles in TNBC.  
Epigenetic alterations, including deregulated 
histone modifications and altered DNA methylation, 
are frequently detectable in human breast cancers, e.g. 
suppressive chromatin modifications or DNA 
hypermethylation mediated transcriptional silencing 
of tumor suppressor genes, which promotes to 
propagation of breast cancer cells [4, 5]. One of the 
important changes is aberrant activity of the 
polycomb repressive complex 2 (PRC2) and 
deregulated expression of its target genes [6]. The 
genes silenced by PRC2 encode, among others, tumor 
suppressors such as apoptosis-related proteins or 
regulators of stem cell signaling [7, 8]. As the catalytic 
component of the PRC2 complex, EZH2 
overexpression has been correlated with poor 
prognosis and inferior outcome in a variety of cancers 
[9-13]. Experimentally, overexpression of EZH2 
reportedly promotes cell proliferation both in vitro [9, 
11] and in vivo [14, 15]. EZH2 is essential for the 
epithelial-to-mesenchymal transition [16, 17], thus 
linking EZH2 overexpression to cell invasion and 
metastasis [18, 19]. Besides, EZH2 mitigates the 
oncogene-induced DNA damage response, thereby 
facilitating also tumor-promoting mutations [14]. 
Inhibition of EZH2 reduced the proliferation of cell 
lines derived from several types of malignancies [20], 
underscoring the potential benefits EZH2 inhibitors 
possess as cancer therapeutics.  
Another epigenetic alteration frequently 
observed across cancer entities is DNA methylation, 
resulting in the silencing of bona fide tumor suppressor 
genes [5, 21]. Recent studies indicate that existing 
DNA methylation marks may be erased by a class of 
methylcytosine dioxygenases termed the ten-eleven 
translocation (TET) family proteins, which include 
TET1, TET2, and TET3 [22, 23]. TET proteins convert 
DNA methylation at the 5’ position of the cytosine 
base (5mC) primarily to 5-hydroxymethylcytosine 
(5hmC) as well as 5-formylcytosine or 
5-carboxylcytosine [22, 23]. Loss of TET1 expression 
and low 5hmC levels have recently been reported in a 
variety of solid tumors and cancer cell lines [24-27], 
thus, suggestive of a tumor-suppressive function.  
Intriguingly, there is now emerging evidence 
implying the highly interrelated relationship between 
DNA methylation and histone modifications, 
particularly lysine methylation, in the vicinity of the 
same gene loci [28, 29]. For example, DNA 
methylation and H3K9 methylation cooperate in cis to 
shut down gene expression via CpG methylation 
accompanied by repressive histone modifications 
decorating this particular DNA region [30-32]. 
However, there is, to the best of our knowledge, little 
evidence that these two fundamental epigenetic 
regulator principles operate in trans with one 
epigenetic regulator controlling another epigenetic 
regulator to ultimately silence a tumor suppressor as 
the actual proto-oncogenic principle. By exploring 
cell-based models, tumor specimens and outcome 
data from human TNBC patients, we uncover here 
that EZH2 and TET1 operate in trans to more tightly 
control target gene activity in TNBC. Besides, we 
further provide demonstrations how to explore it as a 
novel therapeutic vulnerability for this otherwise 
particularly hard-to-treat breast cancer subentity.  
Methods  
Study approval 
Animal subjects 
All animal experiments were conducted in 
accordance with a protocol approved by the 
Institutional Animal Care and Use Committee of 
Zhejiang Provincial People’s Hospital (NO.6/2017 
from 11.07.2017) and conformed to the National 
Institutes of Health Guide for Care and Use of 
Laboratory Animals (Publication No. 85-23, revised 
1996). 
Human subjects 
Use of breast tissue specimens for IHC and 
clinical data was based on informed patient consent, 
and was approved by the Institutional Review Board 
(IRB) of Zhejiang Provincial People’s Hospital.  
In vivo xenograft tumor treatment 
1 x 106 of MDA-MB-231, MDA-MB-436 or MCF7 
breast cancer cells were suspended in 100 µl PBS and 
implanted subcutaneously into the left side of mouse 
armpit of 6-7 weeks old Crl:NU-Foxn1-nu/nu mice 
(Zhejiang Academy of Medical Sciences). When 
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tumors reached a volume of about 50 mm3 (about 5 
mm diameter), treatment was started by 
intraperitoneal administration inhibitors twice a 
week, i.e. GSK343 (5 mg/kg, Medchemexpress, 
HY-13500), Adriamycin (1 mg/kg, Medchemexpress, 
HY-15142), GSK343+Adriamycin combination or 
DMSO as a solvent control. Tumor diameter was 
measured every 3 days with a caliper ruler and tumor 
volume was calculated by the modified ellipsoidal 
formula (tumor volume = 0.5 x length x width2) [33]. 
Cell culture, plasmids and retroviral gene 
transfer 
Breast cancer cell lines MDA-MB-231(TCHu227) 
and MCF7(TCHu74) were purchased from Cell lines 
Cell Bank of Chinese Academy of Sciences; 
MDA-MB-436, MDA-MB-453, BT474 and SKBR3 cell 
lines were kindly provided by Dr. Chuanbing Zang of 
Charité Universitätsmedizin Berlin; MDA-MB-361 
was kindly provided by the laboratory of Dr. Walter 
Birchmeier of Max-delbrueck-center for Molecular 
Medicine. All cell lines were cultivated in DMEM 
supplemented with 10% FBS, 100 U/ml penicillin and 
100 µg/ml streptomycin. FH-TET1-pEF (Addgene 
plasmid # 49792) containing full-length cDNA of 
human TET1 was a gift from Anjana Rao [23] and was 
subcloned into murine stem cell retrovirus (MSCV) 
backbones co-encoding puromycin antibiotic resista-
nce gene. pSuper-retro system was used to stably 
knockdown EZH2, SUZ12 and TET1 gene expression. 
shRNA sequences are shEZH2-1 CGGCTCCTCTAAC 
CATGTTTA; shEZH2-2 GCTGACCATTGGGACAGT 
AAA; shEZH2-3 CAACACAAGTCATCCCATTAA; 
shSUZ12 CGGAATCTCATAGCACCAATA; shTET1 
ACACAACTTGCTTCGATAATT. Retroviral gene 
transfer and antibiotic selection of cell lines were 
previously described [34]. 
Assessment of cell proliferation, viability, 
apoptosis, and SA-β-gal staining 
2 x 104 or 1 x 105 cells were plated in 24-well or 
12-well plates, respectively, and counted at the 
indicated time points with or without treatment. 
EZH2 inhibitor GSK343 was used at 2 µM 
concentration throughout the manuscript unless 
otherwise indicated. 3-deazaneplanocin A (DZNeP) 
was purchased from Selleckchem (S7120). Cell 
numbers and viability were measured using Guava 
ViaCount assay on Guava easyCyte Flow Cytometer 
system (Millipore) and analyzed with the Guava 
CytoSoft software package. Cell-cycle was analyzed 
by BrdU/PI staining and detection of apoptotic cells 
in xenograft-derived tumor sections was analyzed by 
TUNEL staining [35]. SA-β-gal staining was used to 
detect senescent cells in vitro and in vivo. Both 
chromogenic and flow cytometry-based fluorescent 
assays were used in this work. Detailed protocol was 
reported previously [36]. 
Immunoblotting, immunohistochemistry, and 
immunofluorescence 
Immunoblotting (IB), immunohistochemistry 
(IHC) staining of Ki67 in vitro and immunofluor-
escence staining (IF) were performed as previously 
described [35, 37]. For detailed information of 
antibodies, please see supplemental table 1. Patient 
material and xenograft-derived tumor IHC staining 
was performed on formaldehyde-fixed paraffin- 
embedded (FFPE) tissue blocks. Briefly, tissue slides 
were de-waxed in xylene, rehydrated, completed 
antigen retrieval in 0.01 M citrate buffer pH 6.0 at 95 
°C for 5 min and treated with 0.3% H2O2 for 30 min to 
block endogenous peroxidase. The slides were then 
blocked with 5% BSA in PBS for 30 min and incubated 
with primary antibody overnight at 4 °C, followed by 
biotinylated secondary antibody. Diaminobenzidine 
(DAB) was used for chromogenic detection of 
horseradish peroxidase (HRP). IHC staining result of 
patient samples was scored by two experienced 
pathologists, who were blinded to the clinical 
characteristic and survival outcomes, using H-score 
method [38]. Both intensity and proportion of positive 
nuclei were assessed for H3K27me3, EZH2, KDM6A, 
KDM6B and TET1 IHC. Intensity values ranged as 0, 
1, 2 and 3, with 0 being weak, and 3 strong. Proportion 
scores ranged between 0 and 100, representing 
percentage of positive nuclei. A score that ranged 
from 0 to 300 was calculated as the product of the 
intensity and proportion scores. Median value was 
used to cut off high and low expression level.  
Chromatin immunoprecipitation (ChIP), 
quantitative RT-PCR (qRT-PCR) 
ChIP assays were performed using the iDeal 
ChIP-seq Kit for Transcription Factors (Diagenode, 
C01010170) and antibodies against EZH2, H3K27me3 
and TET1, respectively. Lysate of 5 x 106 cells was 
used for each ChIP reaction. Precipitated DNA 
samples were analyzed by quantitative PCR with 
primer pairs specific for the promoters of TET1 and 
TP53 genes. For detailed PCR primer sequences, 
please see supplemental table 2. qRT-PCR was used to 
quantify gene expression as previously described [39]. 
Taqman probes were purchased from Applied 
Biosystems.  
Bisulfite genomic sequencing 
Genomic DNA was extracted from cells using 
TIANamp Genomic DNA Kit (Tiangen Biotech, 
DP304) and subjected to sodium bisulfite treatment 
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using the EpiTect Bisulfite Kit (Qiagen, 59104). 
Treated samples were then amplified by PCR using 
primers designed with MethPrimer [40]: p53 forward: 
TTTTGTTAATAGGAGGTGGGAGTAG; p53 reverse: 
TCACCTAAACTAAAACACAATAACATAATC, 
purified and cloned into pMDTM19-T vector (Takara). 
10 clones were randomly selected for sequencing. 
Dot Blot 
Genomic DNA was extracted from cells using 
TIANamp Genomic DNA Kit (Tiangen Biotech, 
DP304) and sonicated with Bioruptor Plus (Diagen-
ode) for 15 cycles to obtain ~300 bp fragments. DNA 
was denatured with 0.1 M NaOH, incubated at 99 °C 
for 5 min and neutralized with 0.1 volume of 2M 
ammonium sulfate pH7.0. 5 μg DNA was then 
spotted onto Amersham Hybond-N+ membrane (GE 
Healthcare), air-dried and UV-crosslinked. The 
membrane was blocked in 10% milk in TBS containing 
0.1% Tween 20 (TBST) overnight at 4 °C followed by 
primary 5hmC or 5mC antibody (diluted in 5% BSA in 
TBST) incubation for 1 hour at room temperature. 
After washing with TBST, membrane was incubated 
with HRP-conjugated secondary antibody for 1 h at 
room temperature and proceeded with ECL exposure 
and imaging. Dot intensity was quantified by ImageJ 
software. 
TCGA data analysis 
Clinical and Gene expression quantification data 
were downloaded from TCGA. TNBC and non-TNBC 
patients were separated by custom program. DESeq 
[41] was used to test different gene expression 
between TNBCs and non-TNBCs. GSEA is based on 
the ranks of log-transferred p-values with the signs 
defined by the change directions. PRC2 targets set 
(BENPORATH_PRC2_TARGETS) was from 
Molecular Signature Database (MSigDB) [42]. 
RNA-seq data processing 
All fastq files were merged by samples and 
aligned to human genome (GRCh38) using STAR [43] 
with the tolerance of two mismatches. Uniquely 
mapped reads proportions are among 68.4%-77.6%. 
Gene read numbers were counted by HTSeq [44]. The 
values of fragment per kilobase of exon per million 
reads mapped (FPKM) were calculated by custom 
program. The gene different expression tests were 
performed both on shEHZ2 vs. Control and on 
GSK343 vs. Control, respectively, using DESeq in 
multi-factor design. P-values were adjusted by 
Benjamini and Hochberg method. Principal 
component analysis was performed by Julia package 
MultivariateStats (https://github.com/JuliaStats/ 
MultivariateStats.jl) based on the log-transferred 
FPKM values. GSEA is based on the ranks of 
log-transferred DESeq p-values with the signs defined 
by the change directions. 
Data availability 
RNA sequencing data has been deposited in 
NCBI with the following IDs: GEO: GSE112378 and 
are available at: http://www.ncbi.nlm.nih.gov/geo/ 
query/acc.cgi?acc=GSE112378. 
Statistics 
All experiments were conducted in triplicate 
unless otherwise stated. Statistical analyses were 
performed using Graphpad Prism 5.0 package. A 
significance level of p < 0.05 was used throughout the 
study. Differences between two experimental groups 
were analyzed using the unpaired two-tailed 
Student's t-test, growth curves were calculated using 
the two-way ANOVA. Kaplan-Meier curves 
representing survival were compared by the log-rank 
(Mantel-Cox) test. 
Results 
The PRC2 component EZH2 is highly 
expressed in TNBC samples and predicts poor 
survival of patients  
In order to find promising therapeutic targets 
specific for TNBC, we compared RNA sequencing 
data of 116 TNBC samples with 976 non-TNBC 
samples in the Cancer Genome Atlas (TCGA) breast 
cancer dataset. Gene Set Enrichment Analysis (GSEA) 
[42] showed that genes highly expressed in TNBC 
samples were significantly enriched for PRC2 target 
genes (Figure 1A). Therefore, we analyzed the relative 
abundance of the PRC2 components in TCGA dataset, 
including EZH1, EZH2, EED, and SUZ12. 
Interestingly, only EZH2 was highly upregulated in 
TNBC compared to non-TNBC samples, implying that 
EZH2 accounts for the enhanced PRC2 activity 
(Figure 1B, S1A). Considering the heterogeneity of 
TNBC, we then analyzed EZH2 expression in 6 
different TNBC subtypes [45]. Despite their unique 
gene expression profiles, they have consistently 
higher EZH2 expression, except the mesenchymal- 
stem like (MSL) subtype (Figure S1B). We next 
examined 7 breast cancer cell lines, of which 3 were 
derived from TNBC patients (labelled in red), while 
the other 4 represent non-TNBC tumors (depicted in 
blue). Transcript levels of EZH2 were higher in the 3 
TNBC cell lines (Figure 1C), while there was no 
difference on the other H3K27-targeting demethylase 
EZH1 (Figure S1C). The EZH2 expression pattern was 
also confirmed by immunoblot in these cell lines, with 
higher corresponding H3K27me3 levels underscoring 
the enhanced functional activity of EZH2 in the TNBC 
group [46] (Figure 1D). To determine whether levels 
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of EZH2 and H3K27me3 are clinically relevant in an 
independent dataset, we performed immunohisto-
chemistry (IHC) to examine their expression in 97 
TNBC surgical specimens from Zhejiang Provincial 
People’s Hospital (see Study approval in Methods 
section for details). According to their EZH2 
expression, these patients can be categorized into 
EZH2-high and EZH2-low groups by median H-score 
(Figure 1E; see Materials and Methods for details). 
EZH2-high patients often exhibited high levels of 
H3K27me3, as predicted (Figure 1E-F), while other 
known H3K27me3-targeting enzymes, i.e. EZH1, 
KDM6A and KDM6B [47, 48] showed no tight 
correlation with H3K27me3 (Figure S1D). Besides, 
either high levels of EZH2 or H3K27me3 were 
correlated with shorter overall survival (Figure 1G). 
Moreover, the large subgroup of patients presenting 
with an overlap of both high levels of EZH2 and of 
H3K27me3 exhibited the poorest outcome (Figure 
1H). Taken together, these data unveil that TNBC 
enrich for high expression of EZH2 and its target 
module H3K27me3, indicate that their particularly 
high expression predicts poor survival within the 
TNBC group, and further suggest that EZH2/ 
H3K27me3-repressed downstream targets might play 
a critical role in TNBC progression. In turn, we 
hypothesize the EZH2 cascade represent a critical 
vulnerability and a therapeutic target in TNBC. 
 
 
 
Figure 1. High EZH2 and its target H3K27me3 expression in TNBC predicts poor overall survival of patients. (A) Gene Set Enrichment Analysis (GSEA) of 
polycomb repressive complex 2 (PRC2) target genes between TNBC and non-TNBC patients from TCGA-BRCA dataset comprising 1092 patients. Red colors denote a positive 
signal-to-noise ratio (SNR) between the two groups, blue colors indicate a negative SNR. NES: Normalized Enrichment Score. FDR: False Discovery Rate (Benjamini and 
Hochberg)-adjusted p value. (B) Volcano plot of RNA-seq data as in A, showing differential transcription of EZH1, EZH2, EED and SUZ12 between TNBC and non-TNBC. Genes 
above the horizontal red dashed line are those with significantly differential expression. (C) Relative transcription of EZH2 in indicated breast cancer cell lines by qRT-PCR 
analysis. Vertical red dashed line separates TNBC and non-TNBC cell lines. Scale bars indicate mean ± SD. (D) Immunoblot analysis of the indicated proteins in cell lysates from 
cell lines as in C. α-Tubulin and total H3 were used as loading controls. (E) Representative pictures of EZH2 and H3K27me3 immunohistochemical (IHC) staining in TNBC patient 
tumor samples. (F) IHC staining intensity of H3K27me3 in patient samples of EZH2 high vs. low groups. Scale bars indicate mean ± SEM. EZH2 expression level is defined by IHC 
staining intensity of tumor samples. Median value is used as cut-off to separate low and high groups. *** indicates p < 0.001. (G) Kaplan-Meier plot showing overall survival of 
TNBC patients with high vs. low EZH2 (left) or H3K27me3 (right) expression. (H) Kaplan-Meier plot showing overall survival of TNBC patients in indicated expression groups. 
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Figure 2. Inhibition of EZH2 selectively suppresses proliferation of TNBC cell lines. (A) Relative cell number (top) and viability (bottom) of indicated cells treated 
with different concentrations of GSK343 for 2 days and compared with cells treated with solvent control DMSO. (B) Quantification of BrdU/PI cell-cycle analysis by flow 
cytometry showing G1, S, and G2 subpopulations of cells as in A treated with 2 µM GSK343. (C) Quantification (left) and representative pictures (right) of SA-β-gal staining of 
indicated cells treated with 2 µM GSK343 or DMSO for 5 days. (D) Immunoblot analyses of the indicated proteins of cell lysates from cells as in B. α-Tubulin and total H3 were 
used as loading controls. (E) Growth curve of cancer cells transduced with three different shEZH2 or shControl. (F) qRT-PCR analysis of the CCNA1, MKI67 and PCNA transcripts 
in cells expressing shEZH2-1. shEZH2-1 was used here and thereafter for RNA-seq analysis, and was referred as shEZH2 all through the manuscript. shControl-transduced cells 
were used as control. Data are shown as mean ± SD. * indicates p < 0.05. 
 
EZH2 is essential for cell cycle progression of 
TNBC cells 
Therefore, we evaluated the effects of targeting 
EZH2 pharmacologically in TNBC. We tested 
GSK343, a small-molecule inhibitor with EZH2 
specificity [49], at different concentrations on breast 
cancer cells. Lower concentrations of GSK343 (0.5 μM 
and 2 μM) consistently inhibited proliferation of all 
TNBC cell lines, while non-TNBC cell lines were 
much less sensitive to the treatment (Figure 2A, upper 
panel). Moreover, whereas viability of TNBC cells 
decreased under higher doses of GSK343 treatment, 
no increased cell death was observed in non-TNBC 
cells (Figure 2A, lower panels), suggesting that 
GSK343 exerts over a broader dose range anti- 
proliferative and cytotoxic effects selectively in TNBC 
cells. BrdU/PI staining showed that TNBC but not 
non-TNBC cells underwent G1 cell-cycle arrest under 
GSK343 treatment (Figure 2B, S2A). Since we noticed 
morphological changes reminiscent of cellular 
senescence (such as flattened and enlarged cell shape) 
in GSK343-treated cells, we examined senescence- 
associated β-galactosidase activity (SA-β-gal). 
Following GSK343 treatment, TNBC cell lines 
displayed a significant increase of SA-β-gal-positive 
cells, while the fraction of SA-β-gal-positive cells did 
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not change in the non-TNBC group (Figure 2C). 
Cellular senescence is also characterized by the 
formation of heterochromatin foci [50]. Visualized by 
HP1γ immunofluorescence, around 35% of the 
GSK343-treated MDA-MB-231 cells indeed exhibited 
condensed heterochromatin foci (representative cell, 
marked by an arrow in Figure S2B), while virtually 
none (2%) of the non-TNBC MCF7 cells exhibited, if at 
all, much less HP1γ-dense chromatin (Figure S2B). 
We then examined global expression levels of the 
senescence marker H3K9me3 [50] by immunoblot, 
which unveiled a strong induction by GSK343 in 
TNBC cells, with no effect in non-TNBC cells (Figure 
2D). Consistently, proliferation-related proteins 
Cyclin A and PCNA were found down-regulated in 
GSK343-treated TNBC cell lines by immunoblot 
analysis, while non-TNBC cell lines displayed only 
subtle difference (Figure 2D). H3K27me3 was 
detected at much lower, H3K9me3-reciprocal levels in 
GSK343-exposed TNBC cells, but remained 
unchanged in non-TNBC cells (Figure 2D). Similar 
results were obtained with another EZH2 inhibitor, 
DZNep (Figure S2C-D). To further understand the 
pivotal role of EZH2 in TNBC cells, we complemented 
the pharmacological inhibition by a genetic approach 
and knocked-down EZH2 expression by three small 
hairpins (i.e. shEZH2; Figure S2E). Comparable to 
GSK343 treatment, TNBC cells stably transduced with 
shEZH2 exhibited no changes in viability (Figure S2F), 
but had a significantly lower proliferation capacity, as 
further underscored by reduced transcript levels of 
the cell-cycle-related genes CCNA1, MKI67, and 
PCNA (Figure 2E-F). Taken together, EZH2 counters 
senescence and permits high-level proliferation of 
TNBC cells, while its inhibition uncovers a selective 
vulnerability of this highly aggressive breast cancer 
subentity. 
TET1 mediates cell-cycle effects of EZH2 in 
TNBC cells 
To further understand how EZH2 promotes 
cell-cycle progression of TNBC cells, we performed 
RNA sequencing analysis (RNA-seq) of 3 TNBC cell 
lines either treated with 2 μM GSK343, or stably 
transduced with shEHZ2, compared to appropriate 
controls. Principle component analyses (PCA) found 
similar transcriptional alterations in all three TNBC 
cell lines in response to GSK343 treatment or 
knock-down of EZH2 (Figure 3A). As expected, PRC2 
target gene expression was elevated in shEZH2- 
expressing cell lines (Figure S3A). When screening 
important hallmark gene sets by GSEA, E2F target 
genes appeared down-regulated in line with slowed 
cell-cycle progression and senescence induction 
following EZH2 inhibition, and p53 pathway 
components were enriched in shEZH2-transduced 
cells (Figure 3B). We performed qRT-PCR analyses to 
confirm the upregulation of TP53 and its downstream 
target CDKN1A (encoding p21CIP1) in TNBC cell lines 
treated with 2 μM GSK343, while levels of these 
transcripts remained unchanged in non-TNBC cell 
lines (Figure 3C). Because we suspected the TP53 gene 
to be suppressed by PRC2, we performed 
chromosome immunoprecipitation (ChIP) to examine 
whether EZH2 directly binds to the TP53 promoter. 
To our surprise, the anti-EZH2 antibody failed to 
precipitate TP53 promoter sequences in both control 
and GSK343-treated conditions (Figure S3B). Since 
TP53 transcription has been reported to be regulated 
by promoter DNA methylation in breast cancer [51], 
we analyzed the DNA methylation status of the TP53 
promoter by targeted bisulfite sequencing, and 
repetitively observed DNA demethylation at similar 
CpG sites upon GSK343 treatment in TNBC cells 
(Figure S3C). To elucidate the underlying mechanism, 
we focused on three candidate DNA-demethylating 
dioxygenases, TET1, TET2, and TET3, since TET1 was 
previously reported to be down-modulated by PRC2 
in differentiated non-malignant cells [52]. Only TET1 
exhibited a consistent upregulation in all three TNBC 
cell lines stably transduced with shEZH2 (Figure 3D). 
We also analyzed transcription of TET1, TET2, and 
TET3 in cell lines treated with the pharmacological 
EZH2 inhibitor GSK343. Again, TET1 but no other 
dioxygenases showed a dramatic enhancement in the 
two TNBC cell lines tested, while no profound 
changes were detectable for all three TET family 
members in non-TNBC cells (Figure 3E). Basal 
transcript levels of TET1, TET2, and TET3 in TNBC 
compared to non-TNBC cell lines appeared similar 
regarding TET2 and TET3, while mRNA and protein 
expression of TET1 was lower in the TNBC cell lines 
(Figure S3D-E), reciprocal to the EZH2 expression 
pattern (cf. Figure 1D). Considering that TET1 
catalyzes the conversion of the modified genomic base 
5-methylcytosine (5mC) into 5-hydroxymethylcyto-
sine (5hmC), hence playing a key role in active DNA 
demethylation, we performed a genomic DNA dot 
blot analysis to examine the levels of 5hmC and 5mC. 
Consistent with their weak TET1 activity, TNBC cells 
exhibited low 5hmC levels, which increased upon 
GSK343 or shEZH2 treatment, while the non-TNBC 
representative and TET1-strong cell line MCF7 
displayed higher basal levels of 5hmC that remained 
unchanged in response to pharmacological or genetic 
EZH2 inhibition (Figure 3F, left; quantification, right). 
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Figure 3. Inhibition of EZH2 elevates p53 and TET1 expression in TNBC. (A) Principal component analysis (PCA) of RNA-seq data comparing indicated cells 
expressing shEZH2 or treated with GSK343. (B) GSEA profiles of E2F targets and p53 pathway comparing cells with and without EZH2 knock-down. Gene expression profiles 
are combination of MDA-MB-231, MDA-MB-436 and MDA-MB-453 cells. See method section for details. (C) qRT-PCR analysis showing relative transcription of TP53 and 
CDKN1A genes in indicated cells treated with GSK343. Horizontal red dashed line indicates DMSO treated cells as control. (D) RNA-seq analysis of indicated cells with EZH2 
knock-down showing relative expression of TET1, TET2 and TET3 DNA demethylases. (E) Relative transcription of TET1, TET2 and TET3 genes in indicated cells treated with 
GSK343 by qRT-PCR analysis. (F) Dot blot analysis (left) and quantification (right) of global 5hmC and 5mC level in indicated cells GSK343 treatment or EZH2 knock-down 
(DMSO or scrambled shRNA as control). 5 µg genomic DNA was loaded for detection. Data are shown as mean ± SD. * indicates p < 0.05. 
 
TET1 is a direct suppression target of EZH2 
and its downstream H3K27me3 decoration 
Immunoblotting and qRT-PCR also confirmed 
the upregulation of TET1 and downregulation of 
EZH2 proteins in TNBC cells treated with GSK343 in a 
dose dependent manner, which was accompanied by 
a profound activation of p53 signaling and 
downregulation of growth promoting protein E2F1 
(Figure 4A, S4A-C). Interestingly, GSK343 did not 
only inhibit the catalytic activity of EZH2 but also 
downregulated EZH2 transcription and protein 
expression (Figure 4A, S4B-C). It could be explained 
by an indirect inhibition through E2F1 repression, 
which was reported to be a transcriptional activator of 
EZH2 [11]. We further hypothesized that TET1 might 
be a directly suppressed target of the EZH2- 
containing PRC2 complex. Therefore, we performed 
anti-EZH2 and anti-H3K27me3 ChIP, and found 
enrichment of the TET1 promoter in both MDA-MB- 
231 and MDA-MB-436 cells (Figure 4B-C). Moreover, 
the enrichment was significantly repressed by 
GSK343, suggesting that EZH2 suppresses TET1 
transcription through modulation of its H3K27me3 
decoration by PRC2 complex (Figure 4B-C). This was 
further supported by knocking down SUZ12, another 
key component of the PRC2 complex, whose 
downregulation resulted in TET1 induction (Figure 
4D, S4D). Furthermore, by introducing the catalytic 
inactive mutant EZH2-F667I [53], we could verify that 
EZH2 catalytic activity is essential for TET1 
suppression, whereas the inactive EZH2 could not 
inhibit TET1 expression (Figure S4E-F). We also 
analyzed TET1 in situ-expression in the same set of 
TNBC patient samples by immunohistochemistry, 
confirming a negative correlation between TET1 and 
EZH2 protein expression (Figure 4E-F), as well as a 
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negative correlation between TET1 and H3K27me3 
expression in TNBC tumor samples in situ (Figure 
S4G-H). Strikingly, Kaplan-Meier analysis found 
TNBC patients with high expression of TET1 to 
survive longer (Figure 4G). Moreover, patients 
exhibiting both high level of EZH2 and low level of 
TET1 expression presented with the poorest outcome 
(Figure 4H), underscoring the particular inferior 
impact the functional EZH2high/TET1low module but 
no sole EZH2 overexpression or reduced TET1 
expression due to other modes of deregulation in 
TNBC [9, 54]. 
TP53 promoter is directly demethylated by 
TET1 
To further study whether TET1 contributes to the 
effects EZH2 inhibition exerts in TNBC cells, we 
engineered two TNBC cell lines, MDA-MB-231 and 
MDA-MB-436, to stably express TET1 from retroviral 
alleles, i.e. independent of endogenous TET1 
promoter regulation. Growth curve and colony 
formation assays found constitutively TET1-stabilized 
cells to expand more slowly than control cells (Figure 
5A). Similar to our observations in shEZH2- 
transduced and low-concentration-GSK343-treated 
settings (cf. Figures 2A, S2F), viability remained 
 
 
Figure 4. TET1 expression is regulated by PRC2 complex-mediated H3K27me3. (A) Immunoblot analysis of the indicated proteins in lysates from cells treated with 
2 µM GSK343 for 2 days and compared with cells treated with DMSO. (B) ChIP-qPCR analysis of MDA-MB-231 and MDA-MB-436 cells treated with GSK343 or DMSO, using 
an anti-EZH2 antibody and PCR primers specific for TET1 promoter. Input (no immunoprecipitation) as internal control and anti-IgG as negative control. (C) ChIP-qPCR analysis 
of MDA-MB-231 and MDA-MB-436 cells treated with GSK343 or DMSO, using an anti-H3K27me3 antibody and PCR primers specific for TET1 promoter. (D) qRT-PCR analysis 
of TET1 expression in cells expressing shSUZ12. (E) Representative pictures of IHC staining of patient tumor samples showing EZH2 and TET1 expression. (F) TET1 IHC staining 
intensity of patient tumor samples in EZH2 high vs. low groups. Scale bars indicate mean ± SEM. (G) Kaplan-Meier plot showing overall survival of TNBC patients with high vs. 
low TET1 expression. (H) Kaplan-Meier plot showing overall survival of TNBC patient groups with indicated EZH2 and TET1 expression. Data are shown as mean ± SD, unless 
otherwise indicated. * indicates p < 0.05. ** indicates p < 0.01. *** indicates p < 0.001. 
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unaffected by modulating TET1 expression 
(Figure S5A). The TET1-overexpressing samples, 
when compared to vector controls, presented with 
much higher fractions of SA-β-gal-positive and much 
lower percentages of Ki67-positive cells (Figure 5B). 
Consistent with a senescent phenotype, immunofluo-
rescent HP1γ staining demonstrated condensed 
heterochromatin foci in TET1-overexpressing cells 
(Figure 5C).  
 
 
Figure 5. TET1 elevates p53 expression and represses TNBC cell proliferation. (A) Growth curve (top) and colony formation (bottom) analyses of MDA-MB-231 and 
MDA-MB-436 cells expressing TET1 or vector as control. (B) SA-β-gal and Ki67 staining of cells as in A. (C) Representative pictures showing HP1γ immunofluorescent staining 
in cells expressing TET1 or vector. Scale bars = 10 µm. (D) Immunoblot analysis of the indicated proteins in lysates from cells as in A with α-Tubulin and total H3 as loading 
controls. (E) ChIP-qPCR analysis of MDA-MB-231 and MDA-MB-436 cells expressing TET1 or vector as control, using an anti-TET1 antibody and PCR primers specific for TP53 
promoter. Input as internal control and anti-IgG as negative control. (F) Relative cell number of indicated cells expressing shTET1 or vector, 2 days after GSK343 or DMSO 
treatment. (G) SA-β-gal staining of cells expressing shTET1 or vector, treated with GSK343 or DMSO. (H) Immunoblot analysis of the indicated proteins in lysates from cells as 
in G with α-Tubulin as loading control. (I) ChIP-qPCR analysis of cells as in F, using an anti-TET1 antibody and PCR primers specific for TP53 promoter. Input as internal control 
and anti-IgG as negative control. Data are shown as mean ± SD. * indicates p < 0.05. 
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All these cellular characteristics were 
reminiscent of the above reported effects exerted by 
GSK343 treatment or EZH2 knock-down in TNBC 
cells. Immunoblotting analyses documented reduced 
expression levels of the cell-cycle progression markers 
Cyclin A and PCNA in the TET1-stabilized samples. 
Again, total p53, p53-S15 and p21CIP1 levels as well as 
the H3K9me3 mark, all consistent with senescence 
induction, were found elevated in TET1-transduced 
cells (Figure 5D). Since TET1 is a DNA-demethylating 
moiety, we further hypothesized that TET1 may 
reduce methylation at the TP53 promoter, leading to 
the enhanced transcription of TP53 in TET1- 
overexpressing cells. In fact, not only p53 protein 
levels, but also transcription of TP53 was upregulated 
in TET1-overexpressing cells (Figure S5B). We 
performed ChIP analyses with an anti-TET1 antibody, 
and found multiple sites of the TP53 promoter 
occupied by TET1 (Figure 5E). Targeted bisulfite 
sequencing indeed unveiled reduced methylation at 
the TP53 promoter in TET1-overexpressing cells 
compared with control cells (Figure S5C). To 
investigate whether TET1 accounts for the effects of 
EZH2 inhibition or knock-down, we generated 
shTET1-expressing TNBC cells (Figure S5D). In these 
cells with their already low basal TET1 expression 
levels, knocking-down TET1 led to even further 
reduced levels of 5hmC (Figure S5E). Importantly, 
TET1 depletion rescued the growth effects of GSK343 
treatment in the TNBC cell lines (Figure 5F), while it 
had no impact on viability (Figure S5F), thereby 
indicating that EZH2 inhibition largely acts through 
restoration of TET1 in TNBC cells. Accordingly, 
shTET1 prevented senescence induction observed in 
TNBC cells upon exposure to GSK343 (Figure 5G; cf. 
Figure 2C). Immunoblotting also demonstrated that 
GSK343 treatment failed to reduce the expression of 
Cyclin A and PCNA, and to enhance the expression of 
the p53/p21CIP1 cascade as well as H3K9me3 in 
shTET1-stable cells (Figure 5H, S5G). Finally, 
anti-TET1-ChIP provided proof for strongly enhanced 
TET1 binding to the TP53 promoter following GSK343 
treatment, which was completely abrogated in 
shTET1-stable cells (Figure 5I). Intriguingly, inhibition 
of p53 by siRNA could significantly, but not 
completely, rescue the growth effects of GSK343 
treatment in the TNBC cell lines (Figure S5H). This 
indicated that there might be other tumor suppressive 
effects by inhibiting EZH2 besides the 
EZH2-TET1-p53 due to the broadly epigenetic 
regulatory capacity of both EZH2 and TET1. In 
essence, these data pinpoint TET1 as the essential 
negatively regulated downstream target of EZH2 
whose suppression blocks senescence and licenses 
proliferation, thereby underscoring the strong 
rationale for therapeutic inhibition of EZH2 in TNBC. 
Combined treatment with Adriamycin and 
GSK343 significantly reduces TNBC expansion 
in vitro and in vivo 
To test the pharmaceutical potential of GSK343 
in the context of clinically-used standard chemothe-
rapy, we set up combination-treatment experiments 
with the first-line breast cancer drug Adriamycin 
(ADR), a topoisomerase-poisoning anthracycline. 
Viability analyses showed that ADR alone was not 
very effective in killing TNBC cells (Figure 6A, data in 
black). However, combined treatment with 2 μM of 
GSK343, whose limited single-agent impact on cell 
survival we showed earlier in this study, resulted in 
near-total killing of MDA-MB-231 and MDA-MB-436 
cells (Figure 6A, data in red). Immunoblot analyses 
confirmed particularly elevated TET1 and reduced 
H3K27me3 levels in response to the combination 
treatment selectively in the TNBC-representative cell 
lines, but not (or to a much lesser extent) in the 
non-TNBC comparator cell line. Notably, GSK343 
drastically sensitized TNBC cells to ADR treatment by 
enhancing p53 expression and its downstream targets 
PUMA, BAX and BIM, which induced a much 
stronger apoptotic phenotype compared to ADR 
treatment alone (Figure 6A-B, S6A-B). With ultra-low 
concentrations of ADR, however, ADR/GSK343 
combination therapy profoundly increased C12FDG- 
based fluorescent SA-β-gal reactivity in TNBC cells, 
while only evoking a marginal, insignificant signal 
shift in the non-TNBC cell line (Figure 6C, quantified 
in 6D). BrdU/PI-based cell-cycle analysis further 
underscored that TNBC cell lines treated with the 
ADR/GSK343 combination entered an almost 
complete arrest predominantly in the G1-phase with a 
dramatic reduction of the S-phase fraction, whereas 
very little changes were observed in non-TNBC cells 
(Figure 6E). Interestingly, the ultra-low ADR dose, 
probably a good approximation to tissue concentra-
tions actually achieved due to heterogeneous drug 
distribution in the patient’s tumor, evoked in combin-
ation with GSK343 a senescence-reminiscent marker 
pattern by immunoblot analysis in TNBC cells, while 
the same combination had virtually no impact on 
these markers in non-TNBC cells (Figure 6F). 
To test the therapeutic effects of GSK343, ADR, 
or their combination in vivo, we established xenograft 
mouse models by subcutaneous implanting TNBC 
and non-TNBC cell lines into nude mice. When 
tumors became palpable (about 50 mm3), we started 
treatment with DMSO (as a solvent control), GSK343, 
ADR, or an ADR/GSK343 combination (see Materials 
and Methods for details regarding dose/schedule). 
After 21 days of therapy, the tumors in the control 
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group reached the predetermined endpoint. 
Strikingly, the ADR/GSK343 combination was much 
more effective when compared to any single-agent 
treatment regarding growth control of TNBC tumors, 
but was not superior to ADR alone in mice harboring 
non-TNBC tumors (Figure 7A). Moreover, the relative 
growth suppression by the combination therapy was 
by far stronger in the rapidly expanding TNBC 
tumors as compared to the slower progressing 
non-TNBC tumors. We isolated representative tumors 
(Figure S7A), and examined the fractions of senescent 
and apoptotic cells of these xenograft tumors in situ. 
The ADR/GSK343 combination most effectively 
activated TET1 and p53 expression (Figure S7C) and 
subsequently induced senescence, especially in TNBC 
tumors (Figure 7B), where it also achieved the highest 
rate of apoptotic cell death (Figure 7C, S6B). Taken 
together, these results underscore the in vitro-results 
of EZH2 targeting in TNBC cells, and its superior 
activity when administered in combination with 
ADR. Moreover, enhanced apoptosis and execution of 
cellular senescence reflect the critical effector 
mechanisms that particularly harness the highly 
aggressive growth behavior of TNBC, for which a 
conventional chemotherapy strategy is clinically – as 
experimentally reproduced in our hands (Figure 7A) – 
not sufficient. 
 
 
Figure 6. GSK343-treated TNBC cells are sensitive to adriamycin treatment. (A) Viability of indicated cells treated with different concentrations of adriamycin alone 
or together with 2 µM GSK343. (B) Immunoblot analysis of the indicated proteins in lysates from MDA-MB-231 and MCF7 cells treated with 0.05 μg/ml adriamycin alone, or 
together with GSK343, or DMSO. α-Tubulin and total H3 were used as loading controls. (C and D) C12FDG fluorescent analysis by FACS (C) and quantification (D) showing 
SA-β-gal positivity of cells treated with 0.005 µg/ml adriamycin with or without 2 µM GSK343, or DMSO. (E) Quantification of G1, S and G2 subpopulations of BrdU/PI cell-cycle 
analysis of cells as in C. (F) Immunoblot analysis of the indicated proteins in lysates from MDA-MB-231 and MCF7 cells as in C. α-Tubulin and total H3 were used as loading 
controls. Data are shown as mean ± SD. * indicates p < 0.05. 
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Figure 7. Adriamycin and GSK343 combination treatment represses TNBC xenograft tumor progression. (A) Growth curves of xenografted MDA-MB-231, 
MDA-MB-436 and MCF7 cells in NSG mice subjected to GSK343, Adriamycin, GSK343+Adriamycin combination or DMSO. Data are shown as mean ± SD. * indicates p < 0.05. 
(B, C) Representative photos of isolated tumors as in A ex vivo and corresponding SA-β-gal (B) and TUNEL stainings (C) of tumor sections. 
 
Discussion and conclusions 
Intrigued by the hypothesis that cancers lacking 
overtly overexpressed key drivers of oncogenic 
signaling might possess aberrant pro-tumorigenic 
activities rather at the level of epigenetic regulators, 
we identified here overexpression of the PRC2 
subunit EZH2 in conjunction with suppressed 
expression of TET1 as the prominent cancer- 
promoting principle in TNBC. Strikingly, we 
uncovered here a double epigenetic control of 
pro-senescent genes exerted via an EZH2-mediated 
repressive chromatin environment at the TET1 
promoter, thus diminishing its DNA-demethylating 
activity at target genes, among them the pro-senescent 
and pro-apoptotic tumor suppressor p53. The histone 
methyltransferase EZH2 operates as a writer of 
repressive H3K27me3 histone marks, whereas the 
dioxygenase TET1 re-enables gene expression by 
erasing silencing methyl groups within the promoter 
DNA sequence. Unlike normal epigenetic expression 
control often reinforced by combining repressive 
histone methylation and silencing DNA methylation 
at the same target gene promoters, the double 
expression control reported here comes as an unusual, 
linear epigenetic-epigenetic co-deregulation. EZH2- 
mediated H3K27me3 marks shut down TET1 
expression, which, in turn, can no longer demethylate 
its target genes, hence, resulting in the firm repression 
of genes controlled by the deregulated EZH2/ 
H3K27me3/TET1 axis. Patient cohort-wide correla-
tive studies indicate that some TNBC tumor samples 
appear to be driven by either EZH2 overexpression or 
lowered TET1 expression, while the vast majority 
presents as both EZH2high and TET1low. Importantly, 
this writer/eraser liaison is distinctly different from 
the well-known and frequently detectable repressive 
chromatin marks (e.g. H3K9me3) co-decorating the 
very same target promoters that are simultaneously 
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silenced by DNA methylation [55, 56]. Functional 
genetics employing TET1 knock-down position the 
DNA demethylase downstream of EZH2/H3K27me3 
in a linear cascade, thereby uncovering double 
epigenetic control as a hitherto underreported 
oncogenic principle. It remains to be further 
elucidated whether such a mechanism, when 
compared to sole histone or DNA methylation or the 
combination thereof at the same promoter is a 
particularly robust, reinforcing way to shut down 
gene expression, or rather allows much better 
fine-tuning of the ultimate set of target genes. This is a 
particularly interesting question, since we identified 
as a prime target of the EZH2/H3K27me3/TET1 axis 
the p53 tumor suppressor gene, which is much better 
characterized regarding its posttranslational 
expression control via Mdm2-mediated proteasomal 
degradation, and to a much lesser extent as a subject 
of transcriptional control [57]. 
Apparently, breast cancer patients exhibiting 
EZH2high/TET1low co-deregulation experience the 
most detrimental outcome when compared to patient 
cohorts characterized by only one of the two marks. 
Hence, it is not only the overexpression of EZH2 that 
distinguishes TNBC from non-TNBC tumors, it is 
likewise the EZH2high/TET1low label that characterizes 
a particularly poor-outcome subcohort within the 
group of TNBC patients. Given the notoriously low 
responsiveness of TNBC patients to conventional 
chemotherapeutic agents in the clinic, as recapitulated 
in our experimental approaches, more effective, 
molecularly motivated treatment strategies are 
urgently needed for this poor-prognosis patient 
group. As a first approach, we pinpoint here the 
selective vulnerability of TNBC cells to genetic or 
pharmacological inhibition of EZH2 as the upstream 
master principle of EZH2/TET1 deregulation, and 
demonstrate its chemo-resensitizing effect presume-
ably mediated, at least in part, by restoration of the 
previously silenced expression of the pro-apoptotic 
and pro-senescent p53 gene. Future investigations 
will tell whether a therapeutic strategy mirroring the 
linear deregulation of both epigenetic players, namely 
an EZH2 inhibitor/TET1 activator combination, 
perhaps as a “chemo-free” regimen, might produce 
even superior tumor control. Further supporting this 
notion, we have previously shown that over-
expression of TET1 profoundly suppressed tumor 
growth in a human gastric xenograft model [58]. 
Moreover, in the awareness of related dioxygenases, 
especially TET2, frequently presenting with 
inactivating mutations in AML and some lymphoma 
entities [59-61], alternative approaches to compensate 
the diminished DNA-demethylating capacity, e.g. via 
leukemia-approved DNA-hypomethylating agents 
such as Decitabine [62], applied in combination with 
an EZH2 inhibitor, may further exploit the 
TNBC-characteristic EZH2high/TET1low oncogenic 
principle. 
We chose the GSK343 compound to inhibit 
EZH2 because of its high specificity [49]. To our 
surprise, GSK343 not only reduced the activity of 
EZH2, as indicated by down-regulated H3K27me3, 
but also inhibited expression of EZH2 itself, 
suggesting that EZH2 may promote its own stability 
or expression. In normal tissues, EZH2 expression is 
controlled by the E2F pathway and restricted to 
proliferating cells [11]. In our study, we show that 
inhibition of EZH2 by GSK343 leads to upregulation 
of H3K9me3 and suppression of E2F target genes, 
suggesting that a positive feedback loop is present 
between EZH2 and E2F signaling. Thus, EZH2 
targeting might be particularly effective in cancer cells 
whose proliferation depends on high-level signaling 
activity of both the EZH2 histone methyltransferase 
and E2F transcription factors. Moreover, inhibition of 
EZH2 has been shown to upregulate the senescence- 
associated p16INK4A and p14ARF proteins [63], which 
might partially explain the senescent phenotype we 
observed in GSK343-treated cells. The role of 
senescence as a therapeutically exploitable but, 
likewise, potentially resistance-conferring inactivation 
principle is further underscored by the observation 
that TNBC patients are prone in the course of their 
disease to INK4A-ARF deletions. However, the 
patient specimens we examined here stained positive 
for p14ARF in 48.7% and for p16INK4a in 77.1% of the 
cases, thereby implying that a large proportion of 
TNBC patients can build on an intact INK4a/ARF 
functions for GSK343-evoked senescence induction. 
At this stage, we can only speculate why TNBC 
tumors present with this prominent double-epigenetic 
deregulator principle, while lacking distinct lesions in 
typically cancer-associated signaling cascades. 
Previous reports indicate that overexpression of EZH2 
may be due to gene amplification [64] or a 
gain-of-function mutation [65]. High levels of EZH2 
seem to play a role in expanding cancer stem cells to 
initiate breast cancer as shown by EZH2 transgenic 
mice [66]. EZH2 also promotes TNBC invasion by 
cooperating with FoxM1 [67]. TET1 depletion was 
shown to facilitate cell invasion, tumor growth, and 
cancer metastasis in prostate xenograft models and 
correlates with poor survival of breast cancer patients 
[68, 69]. EZH2/TET1 co-deregulation, reflecting the 
critical role of epigenetic regulators in embryonic 
development, tissue formation and cell identity, 
might indeed instruct mammary epithelial cell 
plasticity towards a more stem-like program that 
equips these cells irrespective of activating mutations 
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in classic oncogenes and inactivating defects of tumor 
suppressor genes with aberrant self-renewal capacity, 
and, likewise, intrinsic stem cell-reminiscent chemo-
resistance. Future investigations will clarify, whether 
therapeutic interrogation of TNBC-characteristic 
EZH2/TET1 deregulation not only exerts its efficacy 
via inducing apoptosis and senescence, but by 
ultimately targeting cancer stemness as the crucial 
underlying biological principle.  
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